Raymond James Financial Inc. Purchases Shares of 15,267 DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

Raymond James Financial Inc. bought a new stake in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,267 shares of the company’s stock, valued at approximately $83,000.

Other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of DiaMedica Therapeutics by 29.6% during the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after purchasing an additional 70,070 shares in the last quarter. Blue Trust Inc. grew its stake in shares of DiaMedica Therapeutics by 56.2% during the fourth quarter. Blue Trust Inc. now owns 69,122 shares of the company’s stock worth $375,000 after acquiring an additional 24,875 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of DiaMedica Therapeutics during the fourth quarter valued at about $81,000. Finally, Meridian Wealth Management LLC purchased a new position in shares of DiaMedica Therapeutics in the 4th quarter valued at approximately $148,000. 10.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright boosted their target price on shares of DiaMedica Therapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, March 19th.

DiaMedica Therapeutics Price Performance

Shares of DMAC stock opened at $3.47 on Friday. The business has a fifty day moving average of $5.27 and a 200 day moving average of $5.07. The firm has a market capitalization of $148.71 million, a price-to-earnings ratio of -6.20 and a beta of 1.50. DiaMedica Therapeutics Inc. has a 1 year low of $2.14 and a 1 year high of $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its earnings results on Monday, March 17th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). As a group, equities research analysts expect that DiaMedica Therapeutics Inc. will post -0.59 earnings per share for the current year.

DiaMedica Therapeutics Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.